Methodological exploration of bone marrow stem cell therapy in acute myocardial infarction – how to achieve greater benefit on cardiac outcomes: A systematic review and meta-analysis

Yang, Mei; Qiao, Xu; Liu, Bo; Chen, Xiu; Li, Yi‐Gang

doi:10.17219/acem/66385

Cited by 2 publications

(3 citation statements)

References 32 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the dose controversy, methodologies for cell preparation also have impacts on the prognosis of AMI patients. A systematic review on methodology showed that nonuse of serum or plasma in the cell suspension is associated with a greater reduction in infarct size and a lower risk of all-cause mortality, and heparin usage could diminish the benefit in reducing IS ( Yang et al, 2018 ). Therefore, a well-designed randomized control trial with unified cell preparation and administration doses, as well as rigorous evaluations of cardiac function and long-term clinical outcome follow-up, are required to further establish a clear risk-benefit profile of MSCs.…”

Section: Clinical Trials Using Bmmscs For Ischemic Heart Diseasementioning

confidence: 99%

Bone marrow mesenchymal stromal cell-derived small extracellular vesicles: A novel therapeutic agent in ischemic heart diseases

Chang

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Myocardial injury is a major pathological factor that causes death in patients with heart diseases. In recent years, mesenchymal stromal cells (MSCs) have been generally used in treating many diseases in animal models and clinical trials. mesenchymal stromal cells have the ability to differentiate into osteocytes, adipocytes and chondrocytes. Thus, these cells are considered suitable for cardiac injury repair. However, mechanistic studies have shown that the secretomes of mesenchymal stromal cells, mainly small extracellular vesicles (sEVs), have better therapeutic effects than mesenchymal stromal cells themselves. In addition, small extracellular vesicles have easier quality control characteristics and better safety profiles. Therefore, mesenchymal stromal cell-small extracellular vesicles are emerging as novel therapeutic agents for damaged myocardial treatment. To date, many clinical trials and preclinical experimental results have demonstrated the beneficial effects of bone marrow-derived mesenchymal stromal cells (BMMSCs) and bone marrow-derived mesenchymal stromal cells-small extracellular vesicles on ischemic heart disease. However, the validation of therapeutic efficacy and the use of tissue engineering methods require an exacting scientific rigor and robustness. This review summarizes the current knowledge of bone marrow-derived mesenchymal stromal cells- or bone marrow-derived mesenchymal stromal cells-small extracellular vesicle-based therapy for cardiac injury and discusses critical scientific issues in the development of these therapeutic strategies.

show abstract

Section: Clinical Trials Using Bmmscs For Ischemic Heart Diseasementioning

confidence: 99%

Bone marrow mesenchymal stromal cell-derived small extracellular vesicles: A novel therapeutic agent in ischemic heart diseases

Chang

2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Stem cell therapy is a novel treatment paradigm that has been pursued more in the past few years in both basic science and in the clinic. This treatment is being used to regenerate tissues after disease in neurological and cardiac diseases as well as osteoarthritis . We have previously shown that small cholangiocytes, which may contain a subpopulation of biliary progenitor cells, reduced fibrotic scarring in bile duct ligation (BDL) mice through activation of forkhead box A2 (FoxA2) …”

mentioning

confidence: 99%

“…This treatment is being used to regenerate tissues after disease in neurological and cardiac diseases as well as osteoarthritis. (6)(7)(8) We have previously shown that small cholangiocytes, which may contain a subpopulation of biliary progenitor cells, reduced fibrotic scarring in bile duct ligation (BDL) mice through activation of forkhead box A2 (FoxA2). (9) MicroRNAs (miRNAs) are small noncoding RNAs that can regulate gene expression through direct binding to mRNA or DNA.…”

mentioning

confidence: 99%

Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal‐7 microRNA

McDaniel

Wu²,

Zhou

et al. 2019

Hepatology

View full text Add to dashboard Cite

Cholangiopathies are diseases that affect cholangiocytes, the cells lining the biliary tract. Liver stem cells (LSCs) are able to differentiate into all cells of the liver and possibly influence the surrounding liver tissue by secretion of signaling molecules. One way in which cells can interact is through secretion of extracellular vesicles (EVs), which are small membrane‐bound vesicles that contain proteins, microRNAs (miRNAs), and cytokines. We evaluated the contents of liver stem cell–derived EVs (LSCEVs), compared their miRNA contents to those of EVs isolated from hepatocytes, and evaluated the downstream targets of these miRNAs. We finally evaluated the crosstalk among LSCs, cholangiocytes, and human hepatic stellate cells (HSCs). We showed that LSCEVs were able to reduce ductular reaction and biliary fibrosis in multidrug resistance protein 2 (MDR2)‐/‐ mice. Additionally, we showed that cholangiocyte growth was reduced and HSCs were deactivated in LSCEV‐treated mice. Evaluation of LSCEV contents compared with EVs derived from hepatocytes showed a large increase in the miRNA, lethal‐7 (let‐7). Further evaluation of let‐7 in MDR2‐/‐ mice and human primary sclerosing cholangitis samples showed reduced levels of let‐7 compared with controls. In liver tissues and isolated cholangiocytes, downstream targets of let‐7 (identified by ingenuity pathway analysis), Lin28a (Lin28 homolog A), Lin28b (Lin28 homolog B), IL‐13 (interleukin 13), NR1H4 (nuclear receptor subfamily 1 group H member 4) and NF‐κB (nuclear factor kappa B), are elevated in MDR2‐/‐ mice, but treatment with LSCEVs reduced levels of these mediators of ductular reaction and biliary fibrosis through the inhibition of NF‐κB and IL‐13 signaling pathways. Evaluation of crosstalk using cholangiocyte supernatants from LSCEV‐treated cells on cultured HSCs showed that HSCs had reduced levels of fibrosis and increased senescence. Conclusion: Our studies indicate that LSCEVs could be a possible treatment for cholangiopathies or could be used for target validation for future therapies.

show abstract

Methodological exploration of bone marrow stem cell therapy in acute myocardial infarction – how to achieve greater benefit on cardiac outcomes: A systematic review and meta-analysis

Abstract: Methodological differences in BMCs preparation as well as the use of heparin and serum/ plasma impact on the prognosis of AMI patients.

Cited by 2 publications

References 32 publications

Bone marrow mesenchymal stromal cell-derived small extracellular vesicles: A novel therapeutic agent in ischemic heart diseases

Bone marrow mesenchymal stromal cell-derived small extracellular vesicles: A novel therapeutic agent in ischemic heart diseases

Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal‐7 microRNA

Contact Info

Product

Resources

About